Clinical trial
Phase II Dose Ranging Study of Artesunate
NCT00459615 · U.S. Army Office of the Surgeon General, U.S. Fed · Completed
Key facts
| NCT number | NCT00459615 |
|---|---|
| Title | Phase II Dose Ranging Study of Artesunate |
| Official title | A Phase II, Randomized, Open-Label, Dose-Ranging Study of Intravenous Artesunate Therapy for the Treatment of Acute, Uncomplicated Plasmodium Falciparum Malaria. |
| Lead sponsor | U.S. Army Office of the Surgeon General, U.S. Fed |
| Collaborators | Military Infectious Diseases Research Program (MIDRP) U.S. Army Medical Research and Development Command U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Falciparum Malaria, Uncomplicated Malaria |
| Intervention type | Drug |
| Interventions | Artesunate for Injection |
| Enrollment | 120 |
| Start date | Apr 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Jan 1, 2008 |
| First posted | Apr 12, 2007 |
| Last update posted | Sep 25, 2008 |
| Countries | Kenya, Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: